Adult Patients | TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.
Adult Patients research study
What is the primary objective of this study?
This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and
Romiplostim as bridge therapy for splenectomy in adult patients with primary immune
Who is eligible to participate?
- Persistent or chronic ITP in symtomatic phase.
- 18 years of age or older.
- Indication for splenectomy due to refractory response to a previous therapy.
- Have used eltrombopag or romiplostim to increase platelet count before splenectomy.
- Have undergone splenectomy.
- No informed consent.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Immune Primary Thrombocytopenia
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: May 2014
Completed Date: May 2018
Primary Outcome: Number of patients responding to TPO-mimetics
Secondary Outcome: Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.
Study sponsors, principal investigator, and references
Principal Investigator: Francesco Zaja, Pr.
Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto